说明： SR-18292可有效抑制PGC-1α葡萄糖异生活性并通过调节GCN5和PGC-1α的相互作用来减少HNF4α的共激活。 Information SR-18292 SR-18292 inhibits PGC-1α gluconeogenic activity and reduces co-activation of HNF4α by modulating the interaction between GCN5 and PGC-1α. Targets PGC-1α In vitro SR-18292 is a potent inhibitor of the gluconeogenic gene expression and glucose production in hepatocytes. It increases the interaction of PGC-1α with GCN5 and reduces co-activation of HNF4α by PGC-1α. SR-18292 suppresses HNF4α/PGC-1α gluconeogenic transcriptional function. In vivo SR-18292 reduces blood glucose, strongly increases hepatic insulin sensitivity and improves glucose homeostasis in dietary and genetic mouse models of type 2 diabetes. SR-18292 suppresses hepatic glucose production and increases liver insulin sensitivity in vivo. The liver is a major target of SR-18292 and probably accounts for a significant part of its anti-diabetic effects. Cell Research(from reference) Cell lines：U-2 OS cells overexpressing Ad-GCN5 Concentrations：10 μM Incubation Time：18 h